NYSE:PFEPharmaceuticals
Pfizer (PFE) Stock May Be Fairly Priced On Its 22% Slide
Pfizer stock is coming off a difficult five-year stretch, with shareholders facing a material decline. The current valuation checks suggest the shares may now be priced more as a value opportunity than a premium pharma giant.
Over the past five years, Pfizer has delivered a return of about 21.6% in the red. This puts the focus squarely on whether the current share price already reflects the setbacks in its portfolio and investor sentiment.
Fresh regulatory wins, such as the expanded IBRANCE...